an Entity references as follows:
Mapp Biopharmaceutical is an American pharmaceutical company founded in 2003 by Larry Zeitlin and Kevin Whaley. Mapp Biopharmaceutical is based in San Diego, California. It is responsible for the research and development of ZMapp, a drug which is still under development and comprises three humanized monoclonal antibodies used as a treatment for Ebola virus disease. The drug was first tested in humans during the 2014 West Africa Ebola virus outbreak.